Logo

Bruker Projects Q2 Revenues of $420M-$425M, Exceeding Analyst Expectations

Jul 22, 2020 | staff reporter

NEW YORK - Bruker said today in a filing with the US Securities and Exchange Commission that it expects Q2 2020 revenues of around $420 million to $425 million.

That figure would represent a decline of 13 percent to 14 percent from $490 million in Q2 2019 but would beat analysts' average estimate of $388.8 million.

Bruker had previously projected a year-over-year revenue decline of between 15 percent and 25 percent for the quarter.

The Billerica, Massachusetts-based company said that the better-than-expected projections were driven mainly by stronger demand for its life science products.

Filed under

Proteomics & Protein Research
Mass Spectrometry
Business News
financial estimates
Bruker
Breaking News
The Scan

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.